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Despite significant advances in our understanding of HIV, a cure has not been realized for the more
than 34 million infected with this virus. HIV is incurable because infected individuals harbor cells
where the HIV provirus is integrated into the host’s DNA but is not actively replicating and thus is
not inhibited by antiviral drugs. Similarly, these latent viruses are not detected by the immune sys-
tem. In this Review, we discuss HIV-1 latency and the mechanisms that allow this pathogenic retro-
virus to hide and persist by exploiting the cellular vehicles of immunological memory.Introduction
AIDS was first recognized in the summer of 1981 (Friedman-
Kien, 1981; Gottlieb et al., 1981; Siegal et al., 1981), and HIV
was first isolated two years later (Barre´-Sinoussi et al., 1983)
and was proven to be the cause of AIDS in 1984 (Gallo et al.,
1984; Popovic et al., 1984; Sarngadharan et al., 1984; Schu¨p-
bach et al., 1984). More than 35 million people have died of
AIDS. The virus continues to hit the hardest in Sub-Saharan
Africa, where 1 in every 20 adults is infected. Although there is
no cure for HIV, more than 30 different anti-HIV drugs have
now been approved for clinical use targeting different steps in
the viral life cycle. While not eradicating HIV, combinations of
these agents can routinely drive viral loads down to undetectable
levels. Indeed, HIV is now managed as a chronic rather than
acute disease. Nevertheless, for every 10 people started on an-
tiretroviral therapy in the developing world, 16 people are newly
infected.We clearly do not yet have awinning HIV/AIDS strategy,
and the escalating cost for treatment will become increasingly
difficult for developed countries to meet. Strategies for either
eradicating the virus from infected individuals or boosting their
immune response so that antiviral drugs can be discontin-
ued—a functional cure—are urgently needed.
HIV-1 Latency in CD4+ T Cells
Postintegration HIV latency refers to the rare but extremely
stable proviral reservoir formed within resting memory CD4+
T cells. Latency is established early during acute infection, likely
within days of initial infection (Chun et al., 1998a). Although tran-
scriptionally silent, this reservoir is fully capable of producing in-
fectious virus when the host cell is reactivated by recall antigen
or various cytokines or when antiretroviral therapy (ART) is dis-
continued.
Naive CD4+ T cells exist in a resting state until they encounter
an antigen, after which they undergo activation and proliferation
to generate effector cells that clear the associated pathogen
from the body. The majority of these activated cells die within
a few weeks. However, some of these cells revert back to aresting state and persist as memory T cells that are capable of
responding to the same antigen in the future. It is precisely these
cells that form a primary reservoir for latent HIV proviruses. It is
possible that latent infection reflects infection just as these cells
retreat to a resting state. Because these cells can persist in a
quiescent state for long periods of time, they represent an ideal
cellular reservoir for the maintenance of latent virus. Antigen or
cytokine activation of these cells leads to the induction of tran-
scription factors like NF-kB and NFAT that, in turn, promote
reactivation of the latent HIV proviruses. Following activation,
cytopathic effects or immune responses cause the rapid death
of most HIV-infected cells (Figure 1). Importantly, it was recently
shown that antigen-specific stimulation of patient cytolytic T
lymphocytes (CTLs) prior to virus reactivation from latently in-
fected cells is essential for effective killing of HIV-1-infected cells
in vitro (Shan et al., 2012). This suggests that boosting the CTL
response in infected patients may be necessary to deplete the
HIV reservoir.
Cellular Reservoirs
The introduction of combination ART in 1996 was a major
advance that revolutionized the care of HIV-infected individuals.
These drugs also provided new insights into the dynamics of
HIV-1 replication in vivo. Specifically, a four-phase decline in
virus was detected following ART administration. The initial rapid
phase of decay occurs within the first 2weeks of treatment and is
accompanied by a 99% drop in HIV levels in the blood. This is
largely due to the rapid decline of free virus (t1/2% 6 hr) and pro-
ductively infected cells (t1/2 % 1.6 days) (Ho et al., 1995; Wei
et al., 1995).
The second phase of decay proceeds more slowly and results
mainly from the death of infected macrophages, partially acti-
vated CD4+ T cells, and dendritic cells. The half-life of macro-
phages can be several weeks long, depending on the type of
tissue in which they reside. Macrophages are susceptible to
infection with HIV but are more resistant to the cytopathic effects
of the virus compared to CD4+ T cells (Ho et al., 1986). PartiallyCell 155, October 24, 2013 ª2013 Elsevier Inc. 519
Figure 1. HIV-1 Infection and Reactivation of CD4+ T Cells
HIV-1 infects activated CD4+ T cells, which have increased nucleotide pools, cytokines, and transcription factors compared to nonactivated cells. Most of these
infected cells die due to cytopathic effects of the virus or lysis by HIV-specific CTLs. Cells that revert back to a resting memory T cell survive and may undergo
homeostatic proliferation. Upon initiation of ART, these latently infected cells persist. However, treatment of these cells with reactivating agents causes the cells
to actively produce virus and ultimately leads to either spontaneous cell death or death through immune system clearance.activated CD4+ T cells are also described as having a longer
turnover rate than fully activated CD4+ T cells and are therefore
likely to contribute to the slower decay of the second phase. In
general, the dendritic cell lifespan is highly dependent on
anatomical location and cellular subtype (Shortman and Naik,
2007). Following HIV infection in vitro, myeloid dendritic cells
are capable of surviving for >45 days (Popov et al., 2005). How-
ever, in vivo, it has been shown that peripheral blood myeloid
dendritic cells do not contain detectable HIV DNA following a
6-week ART regimen (Otero et al., 2003). Langerhans cells
have been shown to resist HIV infection unless stressed by
skin abrasion or co-exposed to other sexually transmitted organ-
isms (reviewed by Coleman and Wu, 2009) and, when infected,
have a half-life of about 15 days. For these reasons, HIV-infected
Langerhans cells are not thought to contribute significantly to
the latent reservoir. In addition, follicular dendritic cells, found
in the lymphoid tissues, are capable of trapping and retaining
HIV virions on their surface for several months following infection
(Smith et al., 2001). However, it is unclear whether these cell-
associated virions meaningfully contribute to the latent reservoir
that is able to persist for years in infected subjects on ART.
Taking into account this second phase of decay, it was initially
predicted that 2.3–3.1 years of treatment would be sufficient
to eliminate HIV-1-infected cells, including latently infected lym-
phocytes (Perelson et al., 1997). However, this calculation was
made with the acknowledgment that additional longitudinal
studies were necessary to exclude the presence of very long-
lived infected cells.
In 1995, the first in vivo evidence of the presence of a latent HIV
reservoir was revealed. This was demonstrated by isolating a
highly purified population of resting CD4+ T cells from HIV-1-in-
fected patients and performing inverse PCR to detect integrated
HIV-1 DNA (Chun et al., 1995). At the time, a critical area of inves-520 Cell 155, October 24, 2013 ª2013 Elsevier Inc.tigation was to determine the frequency of latently infected cells
as well as the replication competency of the virus in patients
on ART. Because resting memory CD4+ T cells can persist for
months to years, these cells could represent a long-term viral
reservoir in patients on ART. Indeed, several laboratories
demonstrated that replication-competent virus could persist in
the resting CD4+ T cells of patients on ART regimens and that
these infected cells were present in about 1 in every 106 resting
CD4+ T cells (Chun et al., 1997; Finzi et al., 1997; Wong et al.,
1997). Using direct longitudinal analysis of the decay rate of
the latent reservoir, it was demonstrated that latent cells capable
of producing replication-competent virus had a very long half-life
(43.9 months). Based on this turnover rate, it was estimated to
take 73 years of therapy to eradicate the latent reservoir (Sili-
ciano et al., 2003). Recently, the Siliciano lab identified and char-
acterized proviruses present in viral outgrowth assays that were
not induced by maximal PHA stimulation and showed that a
portion of these proviruses are intact and replication competent.
Taking these noninduced cells into account, statistical modeling
indicated that the number of latently infected cells is 60-fold
larger than originally estimated (Ho et al., 2013 [this issue of
Cell]), proving that eradication of the viral reservoir will be even
more challenging than was previously predicted.
The exact cellular subsets that are responsible for the third and
fourth phases of decline are not yet clear but are likely to include
the well-defined latent reservoir of resting memory CD4+ T cells.
In support of this idea, Chomont et al. identified two viral reser-
voirs within the memory CD4+ T cell pool. Known as central
memory (TCM) and transitional memory (TTM) CD4
+ T cells, these
reservoirs are characterized by differing decay rates in ART-
treated patients and persist by two distinct mechanisms. HIV-in-
fected patients who have normal CD4 counts and who have
begun an early treatment regimen carry a viral reservoir of limited
size that consists mainly of TCM cells. TCM cells proliferate at
extremely low levels and are able to survive for decades,
although this reservoir may be partially depleted at a slow rate
due to CTL killing and the virus’s intrinsic cytopathic effects. In
contrast, HIV-infected patients with low CD4 counts have a viral
reservoir consisting mainly of TTM cells. This is accompanied by
continuous immune activation in the majority of these patients,
including increased levels of IL-7. IL-7 has been shown to induce
proliferation of memory CD4+ T cells andmay induce the homeo-
static proliferation and survival of TTM cells in ART-treated indi-
viduals with low CD4 counts (Chomont et al., 2009). This could
be an additional mechanism by which this latently infected reser-
voir persists for long periods of time. This study also raises the
possibility that earlier therapeutic intervention could more effec-
tively limit the size of this proliferating reservoir.
Although ART is capable of decreasing the viral load to
levels below the limit of detection, the persistence of a latent
reservoir of replication-competent provirus remains a major
obstacle to achieving a cure. It is well known that latently
infected CD4+ T cells can be activated to produce infectious
virus in vitro as well as in vivo. Therefore, stimulation of this
latent reservoir and forcing virus to enter into a productive
viral life cycle may be an essential step in eradicating HIV-1
in infected patients.
Viral Persistence
Themechanism by which virus persists in the presence of ART is
uncertain and may actually involve multiple mechanisms. The
most widely accepted school of thought is that the long-lived
reservoirs of memory CD4+ T cells establish latency early on
and persist for an extremely long time. Another school suggests
that ongoing rounds of replication are occurring perhaps in tis-
sues where drug penetration is decreased (for example, the
CNS and GALT) and that latent infection is established within
these tissues (Gras and Kaul, 2010; Chun et al., 2008). In support
of this latter model, recent studies demonstrated that intensifica-
tion of a suppressive ART regimen by the addition of raltegravir
(an HIV integration inhibitor) results in a temporary increase in
episomal DNA in some HIV-infected patients, consistent with
active viral replication despite ART (Buzo´n et al., 2010).
Conversely, therapy intensification does not appear to affect
reservoir size (Dinoso et al., 2009; Gandhi et al., 2010). Further-
more, longitudinal clonal genotypic analyses demonstrate that
ART-suppressed patients do not develop drug resistance
(Kieffer et al., 2004), suggesting that the latent reservoir is not
evolving during treatment. Importantly, it has also been shown
that there is a lack of HIV-1 evolution in the GALT in patients
that initiated ART during primary infection (Evering et al., 2012).
It should be noted that blips in viral load do not represent repli-
cation of drug-resistant virus but instead simply reflect biological
and statistical variations in levels of the prevailing virus (Nettles
et al., 2005). Even in patients that respond well to ART (e.g., pa-
tients exhibiting undetectable plasma viral loads below 40–50
copies of HIV-1 RNA in standard assays), a low level of free virus
can be detected by sensitive assays (Dornadula et al., 1999).
When considered together, the balance of evidence favors the
conclusion that residual viremia most likely reflects the intermit-
tent production of virus from stable long-lived reservoirs ratherthan ongoing, low-level productive infection. However, this
remains a hotly debated issue.
Mechanisms of Postintegration Latency
A better understanding of the mechanisms of postintegration
latency will be necessary to uncover novel targets and methods
for attacking and eradicating the latent reservoir. In particular, it
will be important to find new ways to reactivate the latent provi-
rus within each and every cell in the reservoir where it resides. It
is also essential that the cellular host be induced to die either as a
result of viral reactivation or as a subsequent immune response
against the virus. In the next sections, we discuss the various
mechanisms that likely underlie HIV latency. However, it is
important to point out that latency is likely a multifactorial pro-
cess. This fact could complicate development of an effective
antilatency therapy.
Site and Orientation of Integration
In most instances, HIV-1 proviral cDNA integrates into regions of
the host genome that are actively transcribed (Schro¨der et al.,
2002). Following integration, the provirus is replicated and tran-
scribed along with the cellular DNA that surrounds it. Some of
these viral RNAs are then translated into viral proteins, whereas
two copies of the full-length viral RNA are incorporated as the
genetic material for new infectious virions. Along with viral
RNA, a number of viral proteins are incorporated into these vi-
rions, including the Gag, Pol, and Env structural proteins. Addi-
tionally, the viral integrase protein, which associates with viral
DNA and the preintegration complex (PIC), is incorporated, as
is Vpr. Various host proteins are included as well. For example,
the cellular LEDGF/p75 is incorporated due to its tightly binding
to integrase (Cherepanov et al., 2003). LEDGF/p75 is believed to
guide the protein complex and viral DNA to intronic regions of
actively transcribed genes (Lewinski et al., 2006). Most latent
proviruses from virally suppressed patients on ART reside in
host genes that are actively transcribed (Han et al., 2004).
Although it may seem contradictory that latent provirus exists
in actively transcribed regions, this phenomenon points to the
potential involvement of transcriptional interference as a mecha-
nism for suppressing expression of the integrated provirus.
One mechanism of transcriptional interference involves pro-
moter occlusion, where the provirus integrates downstream of
the host gene in the same transcriptional orientation or polarity
(Figure 2). This may result in ‘‘readthrough’’ by the host RNA
polymerase II (Pol II), which displaces constitutively expressed
transcription factors like Sp1 that bind to the HIV-1 LTR and
are essential for viral gene expression (Greger et al., 1998).
Furthermore, it has been shown in a Jurkat CD4+ T cell model
(J-Lat cells) that transcriptional interference can be reversed by
inhibiting transcription of the upstream gene or by cooperatively
activating viral transcription initiation and elongation through
viral Tat or TNFa-mediated NF-kB activation (Lenasi et al.,
2008). Specifically, NF-kB can bind the HIV LTR with exception-
ally high affinity and block the upstream elongating RNA Pol II,
thus overcoming transcriptional interference leading to HIV reac-
tivation. Another mechanism of transcriptional interference,
referred to as convergent transcription, occurswhen the provirus
integrates in the opposite orientation or polarity relative to theCell 155, October 24, 2013 ª2013 Elsevier Inc. 521
Figure 2. Major Mechanisms of HIV-1 Latency in CD4+ T Cells
Sequestration of essential transcription factors like NFAT and NF-kB in the cytoplasm leads to silencing of viral gene expression. Two major mechanisms of
transcriptional interference occur in latently infected cells. In promoter occlusion, the host promoter is positioned upstream of the provirus and the host RNA Pol II
reads through the HIV-1 LTR, causing displacement of necessary transcription factors. In convergent transcription, provirus and the host gene are in the opposite
orientation, leading to collision of the RNA Pol II complexes. Levels of cyclin T1, which forms P-TEFb and is important for HIV-1 transcription and Tat trans-
activation, are low in resting CD4+ T cells. DNA methylation and restrictive chromatin structures contribute to transcriptional silencing, leading to HIV-1 latency.host gene (Figure 2). This leads to collision of the RNA Pol II com-
plexes from the host and viral promoters and early arrest of tran-
scription from both promoters or the weaker of the two (Lewinski
et al., 2005). It is also possible that convergent transcription re-
sults in double-stranded RNA when both strands of viral DNA
are elongated. This may lead to silencing of viral transcription
or translation through RNA interference (Hu et al., 2004), RNA-
directed DNA methylation (Morris et al., 2004), or the generation
of antisense RNA (Scherer and Rossi, 2003).
Initiation of Transcription
The 50LTR of HIV contains multiple sites for the binding of cellular
transcription factors, including NF-kB, NFAT, Sp1, and AP1
(Figure 3). These key cellular factors may be activated by
external stimuli to enhance HIV-1 transcription. In resting cells,
NF-kB and NFAT are sequestered in the cytoplasm (and are un-
able to promote HIV-1 transcription in the nucleus) but undergo
nuclear translocation following appropriate cellular activation.
Both NFAT and NF-kB are able to bind to kB sites in the HIV-1
LTR (Kinoshita et al., 1998). However, it is likely that NF-kB plays
a larger role in HIV transcription (Kim et al., 2011). It has been
shown that binding of NF-kB is not sufficient to induce HIV
gene expression, whereas Sp1 is necessary (Perkins et al.,
1993).
In the cytoplasm of resting cells, NF-kB exists as a p50/RelA
heterodimer bound in an inactive form through interactions
with IkBa. In the nucleus of HIV-infected resting cells, NF-kB
p50/p50 homodimers are bound to the 50LTR. The p50/p50
homodimer lacks the essential transactivation domain that is
present in the p50/RelA heterodimer (the prototypical NF-kB
complex). In addition, p50 homodimers can actively inhibit tran-
scription by recruiting HDAC-1 to the LTR and promoting latency522 Cell 155, October 24, 2013 ª2013 Elsevier Inc.through histone deacetylation and chromatin condensation
(Williams et al., 2006). The NF-kB heterodimer is activated by
IKK-mediated phosphorylation of serine-32 and -36 on IkBa
followed by bTrCP-mediated ubiquitylation and degradation of
IkBa by the 26S proteasome. These events enable NF-kB trans-
location to the nucleus and displacement of p50/p50 NF-kB
homodimers. The p50/RelA heterodimers recruit histone acetyl-
transferases (HATs) like p300/CBP, resulting in acetylation of
histone tails and transcriptional activation (Zhong et al., 2002).
To initiate transcription, RelA interacts with the Cdk7 kinase sub-
unit of TFIIH to stimulate phosphorylation of serine-5 within the
CTD of RNA Pol II (Kim et al., 2006). Similarly, interaction of
RelA with P-TEFb results in phosphorylation of the RNA Pol II
CTD at serine-2 and subsequent elongation (Barboric et al.,
2001). P300 also mediates acetylation of RelA at lysines 218,
221, and 310. Acetylation at lysine-310 enhances the transcrip-
tional activity of RelA, whereas acetylation at lysine-218
and -221 enhance DNA binding and make RelA resistant to
IkBa binding.
Following Ca2+ release via the PKC pathway, calcineurin de-
phosphorylates and induces nuclear localization of the cyto-
plasmic components of NFAT. NFAT binds to the 50LTR at two
sets of NFAT-binding sites in addition to the kB sites. Further-
more, it has been shown that CsA, which is a potent inhibitor
of NFAT, is capable of inhibiting HIV LTR promoter activity in pri-
mary cells (Cron et al., 2000). Like NF-kB, NFAT can also bind
p300/CBP and recruit HATs from nuclear extracts of cell lines
(Garcı´a-Rodrı´guez and Rao, 1998).
Our understanding of the key signaling pathways that promote
transcription in active versus latent cells has helped to identify
points of intervention that could be used to overcome latency
and purge the latent reservoir. The non-tumor-promoting
Figure 3. Initiation of Transcription and
Translational Elongation at the HIV-1 LTR
Following cellular activation or drug treatment,
NFAT and NF-kB translocate to the nucleus and
bind sites at the HIV-1 LTR. NFAT and NF-kB re-
cruit p300/CBP to the LTR, resulting in acetylation
of histone tails and transcriptional activation. In the
case of NF-kB, proteosomal degradation of IkBa
permits NF-kB translocation and displacement of
the p50 homodimers. This is followed by Tat-
dependent elongation in which Tat recruits the
P-TEFb complex to TAR. Cdk9 phosphorylates the
CTD of RNA Pol II, resulting in increased proc-
essivity. P-TEFb phosphorylates DSIF and NELF,
resulting in removal of NELF from Pol II and con-
verting DSIF into a positive elongation factor,
thereby promoting productive elongation.phorbol ester prostratin promotes HIV transcription by PKC-
mediated activation of NF-kB, which thereby induces RelA to
bind the latent HIV-1 promoter (Williams et al., 2004). Activation
of the PKC pathway by prostratin also results in downregulation
of the CD4 receptor and the CXCR4 and CCR5 coreceptors on
the host cell, decreasing the likelihood of new infections
(Hezareh et al., 2004). Although NF-kB-inducing agents are
strong activators of HIV-1 transcription, they also cause global
cellular activation andmay induce a toxic inflammatory response
in patients in the form of a cytokine storm.
In addition to PKC activation, there have been attempts to
purge the latent reservoir through global cellular activation using
cytokines. For example, an array of cytokines, including IL-6,
TNFa, and IL-2, are capable of being potent inducers of viral
replication in the resting CD4+ T cells of ART-treated patients
(Chun et al., 1998b). In clinical trials of ART-suppressed patients,
researchers observed no difference in the amount of proviral
DNA and determined that IL-2 had little effect on viral latency
(Dybul et al., 2002; Stellbrink et al., 2002). In another study,
HIV-infected patients were cotreated with ART and a combina-
tion of IL-2 and IFN-g. At the end of the trial, patients rebounded
with high plasma HIV-1 RNA levels when ART was stopped
(Lafeuillade et al., 2001). In patients with near-complete suppres-
sion of plasma viremia (<5 copies/ml), treatment with anti-CD3
antibodies and IL-2 triggered activation and proliferation of
T cells along with stimulation of HIV replication (up to 1,500
copies/ml). However, the anti-CD3/IL-2 therapy was toxic and
resulted in long-lasting depletion of CD4+ T cells in the peripheral
blood and lymph nodes (van Praag et al., 2001). IL-7 is another
cytokine that is capable of activating viral gene expression. For
example, in latently infected cells from SCID-hu (Thy/Liv) mice,
ex vivo treatment with IL-7 was sufficient to reactivate latent vi-
rus while causing minimal cell-cycle progression (Brooks et al.,Cell 155,2003). However, Chomont et al. showed
that IL-7 mediates homeostatic prolifera-
tion and subsequent viral persistence
in patients with low CD4+ T cell levels
through effects on transitional memory
T cells (Chomont et al., 2009). Although
IL-7 and possibly other cytokines can in-
fluence the stability of the HIV reservoir,these findings suggest that global immune activation strategies
may do more harm than good, and that limiting immune activa-
tion in combination with agents like IL-7 might be more effective.
Transcriptional Elongation
The HIV transactivator Tat plays a major role in the elongation
phase of transcription (Figure 3). During the earlier (Tat-indepen-
dent) initiation phase, cellular transcription factors (like NF-kB)
are recruited to the HIV LTR promoter region. This is followed
by the Tat-dependent elongation phase, which promotes much
higher levels of HIV-1 transcription compared to the initiation
phase. When Tat is present, 99% of the transcripts are tran-
scribed to their full length. However, in the absence of Tat,
87% of the initiated transcripts terminate prematurely at posi-
tions +55 to +59 (Kao et al., 1987). This block is due to the activity
of negative transcription elongation factor (N-TEF), which is
composed of the negative elongation factor (NELF) and DRB-
sensitive inducing factor (DSIF). These factors cooperatively
restrict the transcription of other cellular genes (Yamaguchi
et al., 2013). Although these short transcripts predominate in
the absence of Tat, a small amount of full-length transcript is pro-
duced, including Tat, thereafter promoting full-length HIV tran-
scription by positive feedback. To overcome the transcription
block caused by N-TEF, Tat binds to the transactivation-respon-
sive element (TAR), a short nucleotide stem loop located at the 50
end of all HIV transcripts. Following TAR binding, Tat recruits the
P-TEFb complex, composed of CyclinT1 and Cdk9 (Wei et al.,
1998). As part of the P-TEFb complex, Cdk9 phosphorylates
the CTD of RNA Pol II, primarily at serine-2, promoting enhanced
processivity of RNA Pol II (Kim et al., 2002). In addition, P-TEFb
mediates phosphorylation of DSIF and NELF, which results in
removal of NELF from the LTR and allows productive elongation
to begin (Fujinaga et al., 2004; Ivanov et al., 2000).October 24, 2013 ª2013 Elsevier Inc. 523
Transcriptional activation also depends on the acetylation
state of Tat. Tat can be acetylated at lysines 50 and 51 by
CBP/p300 and GCN5, respectively, within the TAR-binding
domain. This leads to the dissociation of Tat from TAR, thus pro-
moting the switch between the early and late phases in HIV tran-
scriptional elongation (Ott et al., 2004). Also, the bromodomain of
p300/CBP-associated factor (PCAF) can bind to acetylated Tat
at lysine-50, thereby competing with the Tat/TAR interaction
and promoting the dissociation of Tat from TAR (Mujtaba et al.,
2002). Disruption of the Tat/CyclinT1/TAR complex via p300-
mediated Tat acetylation facilitates the transfer of Tat to the elon-
gating RNA Pol II complex (Kaehlcke et al., 2003). Furthermore,
both in vitro and in vivo, Tat is deacetylated by human sirtuin 1
(SIRT1), a NAD+-dependent class-II protein deacetylase.
SIRT1-mediated deacetylation allows Tat to return to its unace-
tylated form, thereby enabling the initiation of a new transcription
cycle (Pagans et al., 2005). In addition, experimental and compu-
tational studies performed by Weinberger et al. (2005) demon-
strate how stochastic fluctuations (noise) in the activity of the
LTR governed by Tat can influence the viral latency decision
(Weinberger et al., 2005). This provides further evidence for the
importance of Tat in regulating HIV-1 latency.
Levels of active P-TEFb are key in promoting the switch to
productive elongation and therefore play a large role in control-
ling the expression levels of viral genes. P-TEFb is inactive
when its components CyclinT1 and Cdk9 are bound to the 7SK
small nuclear ribonucleoprotein complex containing the inhibi-
tory molecule HEXIM1 (Yik et al., 2003). The release of P-TEFb
from HEXIM1 is mediated through stress-inducing agents,
including the small-molecule hexamethylene biacetamide
(HMBA) (Contreras et al., 2007). Choudhary et al. showed that
HMBA-treated resting memory CD4+ T cells from ART-sup-
pressed patients were reactivated through phosphorylation of
the CTD of RNA Pol II in a Cdk9-dependent manner. HMBA
increases the nuclear expression level of Cdk9, which is then
recruited to the LTR by Sp1 (Choudhary et al., 2008).
There has been great interest in a novel group of transcrip-
tional regulators shown to control viral gene expression. Recent
studies demonstrated the effectiveness of JQ1 and other bromo-
domain (BET family) inhibitors in inducing latent reactivation in
cell lines and primary cell models of HIV latency (Banerjee
et al., 2012; Bartholomeeusen et al., 2012; Li et al., 2013). Spe-
cifically, it was shown that bromodomain-containing protein 4
(Brd4) could compete with HEXIM1 for P-TEFb binding. There-
fore, inhibiting the binding of Brd4 to P-TEFb could promote
increased binding of Tat to P-TEFb. In contrast, Boehm et al.
recently showed that BET inhibitors like JQ1 are dependent on
P-TEFb but independent from Tat. In addition, Brd2 was identi-
fied as a new Tat-independent suppressor of HIV transcription
(Boehm et al., 2013). This mechanism of action has not yet
been fully worked out. Interestingly, it is also known that
HMBA increases the level of active P-TEFb-Brd4 complexes
(He et al., 2006). The BET family therefore represents a promising
new target for therapies aimed at overcoming HIV-1 latency.
Chromatin Modification
The expression of genes, including those of integrated HIV-1, is
dependent on chromatin structure, which can be altered by524 Cell 155, October 24, 2013 ª2013 Elsevier Inc.epigenetic modifications. The main structural units of chromatin
are nucleosomes, which consist of pairs of four core histones
(H2A, H2B, H3, and H4) that form an octamer and become
enwrapped by 1.7 turns of DNA (147 base pairs). When formed
around promoters, these structures can epigenetically deter-
mine whether the associated genes are expressed or not. For
example, a genome in a compact structure bound tightly by
nucleosomes is transcriptionally repressed due to blockade of
the promoter region from the transcriptional machinery; DNA in
this state is called heterochromatin. In contrast, euchromatin re-
fers to the relaxed and transiently open state of chromatin, which
encourages transcription. It is known that changes in chromatin
condensation status can be mediated through chromatin-
remodeling complexes that use ATP to disrupt nucleosome-
DNA contacts, move nucleosomes along DNA, and remove or
exchange nucleosomes. However, changes in chromatin struc-
ture are also brought about by various posttranslational modifi-
cations, including acetylation and methylation.
Histone acetyl transferases (HATs) catalyze the addition of
acetyl groups to target histones, whereas histone deacetylases
(HDACs) remove these acetyl groups. These opposing functions
of HATs and HDACs allow for switching between different acet-
ylation states and determine whether genes are transcriptionally
activated or repressed, respectively. In terms of HIV-1 therapy,
there has been great interest in using HDAC inhibitors to block
HDAC deacetylase activity, which would create a less-repres-
sive chromatin state and would allow for HIV transcription. Early
experiments showed that, independent of the viral integration
site, the 50LTR of HIV contains two nucleosomes, nuc-0 and
nuc-1 (Verdin et al., 1993). Nuc-1 is rapidly and specifically dis-
rupted following treatment with HDAC inhibitors, thus allowing
for increased HIV-1 transcription via chromatin modification
(Van Lint et al., 1996). More recent studies revealed that multiple
DNA-binding complexes could be responsible for the recruit-
ment of HDACs to initiator and enhancer regions of the HIV-1
promoter, thereby inducing repressive effects on chromatin
structure. HDAC1 is recruited by a number of transcription fac-
tors to the 50LTR, including (but not limited to) late SV40 factor
(LSF) (He and Margolis, 2002), activating protein 4 (AP-4) (He
and Margolis, 2002), NF-kB p50/p50 homodimers (Williams
et al., 2006), C promoter binding factor 1 (CBF-1) (Tyagi and
Karn, 2007), and Sp1 (Jiang et al., 2007). Although four different
classes of HDACs exist, class-I HDACs (HDAC1, 2, and 3) domi-
nate at the HIV LTR in CD4+ cell line models (Keedy et al., 2009).
As previously noted, increasing HIV-1 transcription represents
a possible strategy for eradicating latent provirus from HIV-1-in-
fected patients. Initially, HDAC inhibitors held promise as good
candidates for viral purging because they failed to promote
global T cell activation yet could activate the virus. These cells
could also act on a broad range of cellular types, not just
T cells. However, a prominent concern is their ability to affect
multiple biological processes, as reflected by cancer studies
showing that HDAC inhibitors affect transcription of about 10%
of cellular genes (Glaser et al., 2003).
Initial studies in patients using valproic acid (VPA), an HDAC1
inhibitor, were encouraging. When given to patients on intensi-
fied ART, VPA was reported to accelerate the reduction of HIV-
infected resting T cells (Lehrman et al., 2005). Unfortunately, later
reports did not demonstrate the same decay of infected resting
T cells following VPA treatment (Sagot-Lerolle et al., 2008; Sili-
ciano et al., 2007). Another more potent class I HDAC inhibitor,
suberoylanilide hydroxamic acid (SAHA), can induce HIV-1 tran-
scription in resting CD4+ T cells from patients on ART (Archin
et al., 2009). In other studies, treatment with either VPA or
SAHA results in synergistic activation of latent HIV in patient
PBMCs when combined with the PKC agonist prostratin (Reuse
et al., 2009). In addition to prostratin, another PKC agonist,
bryostatin, also had synergistic effects when used in combina-
tion with HDAC inhibitors (Pe´rez et al., 2010). Combinatorial stra-
tegies, in which multiple pathways are targeted, are likely to be a
more effective strategy for clearing the latent reservoir to levels
that are necessary for achieving a cure.
DNA Methylation
Transcriptional regulation by DNA methylation is catalyzed by
DNA methyltransferases and occurs largely at CpG dinucleo-
tides. DNA methylation is associated with gene silencing and is
present at high levels within heterochromatic regions ofmamma-
lian DNA. CpG methylation occurs at the 50LTR of HIV-1 and
likely acts by preventing the binding of essential transcription
factors such as NF-kB and Sp1 (Bednarik et al., 1991). In a study
by Kauder et al., it was demonstrated that, during latency, the
HIV-1 promoter is hypermethylated at two CpG islands sur-
rounding the transcriptional start site in both J-Lat cell lines
and in primary CD4+ T cells. One of the two methylated CpG
islands is occupied by methyl-CpG-binding protein 2 (MBD2)
and HDAC2, thereby promoting a transcriptionally repressive
state. Inhibition of DNA methylation with 5-aza-20deoxycytidine
(aza-CdR) prevents the recruitment of MBD2 and HDAC2 and
synergizeswith NF-kBactivators to promote a dramatic increase
in viral gene expression (Kauder et al., 2009). Furthermore, in
another study by Blazkova et al., CpG methylation of the HIV-1
50LTR was shown to prevent reactivation in an in vitro model of
latency and in memory CD4+ T cells from HIV-infected patients.
This methylation pattern was responsible for the maintenance
but not establishment of HIV-1 latency (Blazkova et al., 2009).
In addition, the combination of 5-aza-CdR and prostratin had a
synergistic effect on HIV-1 reactivation. In contrast, recent
studies have demonstrated that only 2.4% of HIV 50LTRs con-
tained methylated CpG dinucleotides in infected individuals
receiving ART (Blazkova et al., 2012). Therefore, it is likely that
DNA methylation at the HIV 50LTR plays a less prominent role
in maintenance of the latent reservoir than other mechanisms
described in this Review.
Examples of HIV Cures
Thirty years ago, the term ‘‘HIV cure’’ was equated to complete
eradication of virus from an HIV-infected patient. Now there is
mounting evidence supporting the concept of a ‘‘functional
cure’’ represented by the persistence of a low and stable viral
load in the absence of ART. Timothy Ray Brown, also known
as ‘‘the Berlin patient,’’ appears to represent an HIV cure
involving complete eradication of the virus, as recent detection
of low level residual virus may be artifactual (Yukl et al., 2013).
Brown was an HIV-positive patient who developed acute
myeloid leukemia and was treated for his cancer by stem celltransplantation from an individual who was homozygous for
the CCR5 gene variant D32 (Allers et al., 2011). Individuals with
this mutation express a nonfunctional truncated variant of the
CCR5 coreceptor and are therefore resistant to infection with
CCR5-tropic viral strains. This treatment resulted in eradication
of virus from his body without the need for any further ART
following transplant.
Functional cures have also been described likely reflecting an
enhanced immune response against the virus. For example,
recent studies have identified 14 HIV patients who maintained
long-lasting control of viremia for several years following the
interruption of ART (Sa´ez-Cirio´n et al., 2013). These 14 patients
were distinct from elite controllers in that they lacked protective
HLA alleles and did not develop strong HIV-specific T cell re-
sponses. Of note, these patients initiated ART during the very
early primary stage of HIV infection. In contrast, most patients
begin treatment regimens during the later chronic stage of HIV
infection. Follow-up studies showed that, following the interrup-
tion of therapy in these individuals, long-lived resting CD4+
T cells represented only a minor population within the total viral
reservoir compared to patients who initiated therapy later. These
individuals provide additional evidence that a functional cure is
possible and that treatment during the early stage of infection
may significantly decrease the formation of viral reservoirs in
longer-lived memory cells.
Further support for the concept of very early treatment may be
found in a recent report of a baby girl from Mississippi infected
with HIV either in utero or during birth. She received three antire-
troviral drugs within 31 hr of birth and then continued therapy for
the first 15 months of her life until her mother stopped adminis-
tering drugs for several months. Surprisingly, since terminating
the treatments, the child has not exhibited a viral rebound nor
any detectable virus in her blood. This case again raises the pos-
sibility that early and aggressive treatment might lead to a cure,
although whether this situation represents full eradication or a
functional cure remains unclear. Although this case is less rele-
vant in developed countries where expectant mothers with HIV
routinely receive treatment to prevent transmission, it is highly
relevant for developing regions like Sub-Saharan Africa, where
it is more common for untreated HIV-positive mothers to give
birth. In sum, these studies suggest that a ‘‘cure’’ may not require
a complete viral purge but instead may be achieved functionally
byminimizing the size of the latent reservoir via early and aggres-
sive antiretroviral treatment. In addition, it is possible that a func-
tional cure can be attained through pharmacological agents that
cause the reactivation of a significant proportion of the latent
proviruses. Because it may not be necessary to reactivate every
cell in the viral reservoir, it is possible that we are, in fact, closer to
a functional cure than previously thought.
Concluding Remarks
A key goal in the field of HIV research is to identify a safe, effec-
tive, and scalable cure for the roughly 34 million people currently
infected with HIV around the world. The ability to cure infected
individuals would yield both a cost-effective prevention strategy
for curbing the spread of HIV and a solution to the unsustainable
global cost of treatment by eliminating the need for lifelong
antiviral therapy. Currently, we are only reaching approximatelyCell 155, October 24, 2013 ª2013 Elsevier Inc. 525
one-third of those infected who need treatment based on new
WHO criteria. Further, for every 10 individuals placed on treat-
ment, 16 more are newly infected. Clearly, we do not yet have
a winning strategy, particularly in sub-Saharan Africa, where
the virus is hitting the hardest. The development of a cure for
HIV infection would be game changing. Our progress toward a
cure will be enhanced by a better understanding of themolecular
underpinnings of HIV latency. We also need a more systematic
effort to identify viral activating agents that can be combined
to form a highly effective cocktail for purging virus from the latent
reservoir. Similarly, more work is required to identify the full
range of cells that comprise the latent reservoir and the nature
of the immune factors that drive its maintenance. We also
need to prepare for the possibility that rousing virus from its
transcriptional slumber in latently infected cells will not lead to
clearance of the cellular host. If this is the case, additional tech-
nologies will be needed to kill these cells, thereby depleting the
reservoir. Complete viral eradication is a desirable but lofty
goal. Alternatively, it may be possible to enhance the intrinsic
immune response against the virus in a manner that allows anti-
viral drug discontinuation even though the virus remains—a
functional cure. Such a functional cure may, in fact, be easier
to achieve than complete viral eradication, although the latter
remains the ultimate goal. Certainly the recent individual cases
in which at least a functional cure has been achieved provide
hope for the field. However, it will be important to ensure that
new antilatency therapies are not only deployable in developed
countries but instead can be used throughout the world.
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